Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fruquintinib (HMPL-013) is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 30.00 | |
5 mg | In stock | $ 48.00 | |
10 mg | In stock | $ 77.00 | |
25 mg | In stock | $ 119.00 | |
50 mg | In stock | $ 150.00 | |
100 mg | In stock | $ 263.00 | |
500 mg | In stock | $ 653.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 53.00 |
Description | Fruquintinib (HMPL-013) is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities. |
Targets&IC50 | VEGFR1:33 nM, VEGFR3:0.5 nM, VEGFR2:35 nM |
Synonyms | HMPL-013 |
Molecular Weight | 393.39 |
Formula | C21H19N3O5 |
CAS No. | 1194506-26-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 6 mg/mL (15.25 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Fruquintinib 1194506-26-7 Angiogenesis Tyrosine Kinase/Adaptors VEGFR HMPL-013 Inhibitor Vascular endothelial growth factor receptor HMPL013 inhibit HMPL 013 inhibitor